A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Gilead goes long-acting in HIV
Sunlenca gets a US green light at the second time of asking, but combination success will be vital to it fulfilling its promise.
